Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices.

Dhand R, Mahler DA, Carlin B, Hanania N, Ohar J, Pinto-Plata V, Shah T, Eubanks D, Braman SS.

Respir Care. 2018 Mar 20. pii: respcare.05715. doi: 10.4187/respcare.05715. [Epub ahead of print]

PMID:
29559537
2.

Evaluation of Dyspnea in the Elderly.

Mahler DA.

Clin Geriatr Med. 2017 Nov;33(4):503-521. doi: 10.1016/j.cger.2017.06.004. Epub 2017 Jul 17. Review.

PMID:
28991647
3.

Prevalence of Low Peak Inspiratory Flow Rate at Discharge in Patients Hospitalized for COPD Exacerbation.

Sharma G, Mahler DA, Mayorga VM, Deering KL, Harshaw O, Ganapathy V.

Chronic Obstr Pulm Dis. 2017 Jul 15;4(3):217-224. doi: 10.15326/jcopdf.4.3.2017.0183.

4.

Efficacy of Indacaterol/Glycopyrronium in Patients with COPD Who Have Increased Dyspnea with Daily Activities.

Mahler DA, Keininger DL, Mezzi K, Fogel R, Banerji D.

Chronic Obstr Pulm Dis. 2016 Sep 9;3(4):758-768. doi: 10.15326/jcopdf.3.4.2016.0138.

5.

Peak Inspiratory Flow Rate as a Criterion for Dry Powder Inhaler Use in Chronic Obstructive Pulmonary Disease.

Mahler DA.

Ann Am Thorac Soc. 2017 Jul;14(7):1103-1107. doi: 10.1513/AnnalsATS.201702-156PS.

PMID:
28481631
6.

Greater dyspnea is associated with lower health-related quality of life among European patients with COPD.

Gruenberger JB, Vietri J, Keininger DL, Mahler DA.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 20;12:937-944. doi: 10.2147/COPD.S123744. eCollection 2017.

7.

Exertional dyspnoea in COPD: the clinical utility of cardiopulmonary exercise testing.

O'Donnell DE, Elbehairy AF, Faisal A, Webb KA, Neder JA, Mahler DA.

Eur Respir Rev. 2016 Sep;25(141):333-47. doi: 10.1183/16000617.0054-2016. Review. Erratum in: Eur Respir Rev. 2016 Dec;25(142):513.

8.

Efficacy and safety of LABA/LAMA fixed-dose combinations approved in the US for the management of COPD.

Banerji D, Mahler DA, Hanania NA.

Expert Rev Respir Med. 2016 Jul;10(7):767-80. doi: 10.1080/17476348.2016.1190276. Epub 2016 May 30. Review.

PMID:
27223863
9.

Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3).

Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R.

Respir Med. 2016 Jun;115:39-45. doi: 10.1016/j.rmed.2016.03.015. Epub 2016 Mar 22.

10.

FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.

Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, Lloyd M, Patalano F, Banerji D.

Am J Respir Crit Care Med. 2015 Nov 1;192(9):1068-79. doi: 10.1164/rccm.201505-1048OC.

PMID:
26177074
11.

Indacaterol vs tiotropium in COPD patients classified as GOLD A and B.

Mahler DA, Kerstjens HA, Donohue JF, Buhl R, Lawrence D, Altman P.

Respir Med. 2015 Aug;109(8):1031-9. doi: 10.1016/j.rmed.2015.05.012. Epub 2015 May 22.

12.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí AA, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir Rev. 2015 Jun;24(136):159-72. doi: 10.1183/16000617.00000315. Review.

13.

A perspective on web-based information for patients with chronic lung disease.

Mahler DA, Petrone RA, Krocker DB, Cerasoli F.

Ann Am Thorac Soc. 2015 Jul;12(7):961-5. doi: 10.1513/AnnalsATS.201502-104PS.

PMID:
25923358
14.

Prospective use of descriptors of dyspnea to diagnose common respiratory diseases.

Chang AS, Munson J, Gifford AH, Mahler DA.

Chest. 2015 Oct;148(4):895-902. doi: 10.1378/chest.15-0308.

PMID:
25905554
15.

An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Am J Respir Crit Care Med. 2015 Apr 1;191(7):e4-e27. doi: 10.1164/rccm.201501-0044ST.

PMID:
25830527
16.

An official American Thoracic Society/European Respiratory Society statement: research questions in COPD.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, MacNee W, Make BJ, Rennard SI, Stockley RA, Vogelmeier C, Anzueto A, Au DH, Barnes PJ, Burgel PR, Calverley PM, Casanova C, Clini EM, Cooper CB, Coxson HO, Dusser DJ, Fabbri LM, Fahy B, Ferguson GT, Fisher A, Fletcher MJ, Hayot M, Hurst JR, Jones PW, Mahler DA, Maltais F, Mannino DM, Martinez FJ, Miravitlles M, Meek PM, Papi A, Rabe KF, Roche N, Sciurba FC, Sethi S, Siafakas N, Sin DD, Soriano JB, Stoller JK, Tashkin DP, Troosters T, Verleden GM, Verschakelen J, Vestbo J, Walsh JW, Washko GR, Wise RA, Wouters EF, ZuWallack RL; ATS/ERS Task Force for COPD Research.

Eur Respir J. 2015 Apr;45(4):879-905. doi: 10.1183/09031936.00009015. Review.

17.

Recent advances in dyspnea.

Mahler DA, O'Donnell DE.

Chest. 2015 Jan;147(1):232-241. doi: 10.1378/chest.14-0800. Review.

PMID:
25560861
18.

Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD.

Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Lettis S, Calverley PM.

Ann Am Thorac Soc. 2015 Jan;12(1):27-34. doi: 10.1513/AnnalsATS.201409-413OC.

PMID:
25490706
19.

Response.

Dong YH, Chang CH, Mahler DA.

Chest. 2014 Dec;146(6):e212-3. doi: 10.1378/chest.14-1837. No abstract available.

PMID:
25451366
20.

One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD.

Donohue JF, Hanania NA, Make B, Miles MC, Mahler DA, Curry L, Tosiello R, Wheeler A, Tashkin DP.

Chest. 2014 Dec;146(6):1531-1542. doi: 10.1378/chest.14-0117.

21.

Prospective validation of the endurance shuttle walking test in the context of bronchodilation in COPD.

Borel B, Pepin V, Mahler DA, Nadreau É, Maltais F.

Eur Respir J. 2014 Nov;44(5):1166-76. doi: 10.1183/09031936.00024314. Epub 2014 Sep 3.

22.

Recent advances in COPD disease management with fixed-dose long-acting combination therapies.

Bateman ED, Mahler DA, Vogelmeier CF, Wedzicha JA, Patalano F, Banerji D.

Expert Rev Respir Med. 2014 Jun;8(3):357-79. doi: 10.1586/17476348.2014.910457. Epub 2014 May 7. Review.

PMID:
24802656
23.

Antagonism of substance P and perception of breathlessness in patients with chronic obstructive pulmonary disease.

Mahler DA, Gifford AH, Gilani A, Waterman LA, Hilton J, Chang AS, Kupchak BR, Kraemer WJ.

Respir Physiol Neurobiol. 2014 Jun 1;196:1-7. doi: 10.1016/j.resp.2014.02.008. Epub 2014 Feb 25.

PMID:
24582719
24.

Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of randomized controlled trials.

Dong YH, Chang CH, Wu FL, Shen LJ, Calverley PMA, Löfdahl CG, Lai MS, Mahler DA.

Chest. 2014 Jun;145(6):1286-1297. doi: 10.1378/chest.13-2137. Review.

PMID:
24504044
25.

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, Sanford L, Lettis S, Crim C, Calverley PM.

Lancet Respir Med. 2013 May;1(3):210-23. doi: 10.1016/S2213-2600(13)70040-7. Epub 2013 Apr 12. Erratum in: Lancet Respir Med. 2013 May;1(3):186.

PMID:
24429127
26.

Minimal clinically important differences in pharmacological trials.

Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi: 10.1164/rccm.201310-1863PP. Review.

PMID:
24383418
27.

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study.

Mahler DA, Decramer M, D'Urzo A, Worth H, White T, Alagappan VK, Chen H, Gallagher N, Kulich K, Banerji D.

Eur Respir J. 2014 Jun;43(6):1599-609. doi: 10.1183/09031936.00124013. Epub 2013 Oct 31.

28.

Effect of fluticasone propionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD.

Maltais F, Mahler DA, Pepin V, Nadreau E, Crater GD, Morris AN, Emmett AH, Ferro TJ.

Eur Respir J. 2013 Aug;42(2):539-41. doi: 10.1183/09031936.00074113. No abstract available.

29.

Comparison of dry powder versus nebulized beta-agonist in patients with COPD who have suboptimal peak inspiratory flow rate.

Mahler DA, Waterman LA, Ward J, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2014 Apr;27(2):103-9. doi: 10.1089/jamp.2013.1038. Epub 2013 Jun 8.

PMID:
23745526
30.

Effect of increased blood levels of β-endorphin on perception of breathlessness.

Mahler DA, Gifford AH, Waterman LA, Ward J, Kraemer WJ, Kupchak BR, Harver A.

Chest. 2013 May;143(5):1378-1385. doi: 10.1378/chest.12-1541.

PMID:
23715032
31.

Opioids for refractory dyspnea.

Mahler DA.

Expert Rev Respir Med. 2013 Apr;7(2):123-34; quiz 135. doi: 10.1586/ers.13.5. Review.

PMID:
23547989
32.

Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity.

Mahler DA, Buhl R, Lawrence D, McBryan D.

Pulm Pharmacol Ther. 2013 Jun;26(3):348-55. doi: 10.1016/j.pupt.2013.02.006. Epub 2013 Feb 19.

PMID:
23434446
33.

Inflammation in COPD: implications for management.

Sethi S, Mahler DA, Marcus P, Owen CA, Yawn B, Rennard S.

Am J Med. 2012 Dec;125(12):1162-70. doi: 10.1016/j.amjmed.2012.06.024. Review.

PMID:
23164484
34.

Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler.

Mahler DA, Waterman LA, Gifford AH.

J Aerosol Med Pulm Drug Deliv. 2013 Jun;26(3):174-9. doi: 10.1089/jamp.2012.0987. Epub 2012 Oct 1.

PMID:
23025451
35.

Longitudinal changes in patient-reported dyspnea in patients with COPD.

Mahler DA, Ward J, Waterman LA, Baird JC.

COPD. 2012 Aug;9(5):522-7. doi: 10.3109/15412555.2012.701678. Epub 2012 Aug 9.

PMID:
22876883
36.

Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD.

Hareendran A, Leidy NK, Monz BU, Winnette R, Becker K, Mahler DA.

Int J Chron Obstruct Pulmon Dis. 2012;7:345-55. doi: 10.2147/COPD.S29571. Epub 2012 May 28.

37.

Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison.

Mahler DA, D'Urzo A, Bateman ED, Ozkan SA, White T, Peckitt C, Lassen C, Kramer B; INTRUST-1 and INTRUST-2 study investigators.

Thorax. 2012 Sep;67(9):781-8. Epub 2012 Apr 27.

PMID:
22544891
38.

An official American Thoracic Society statement: update on the mechanisms, assessment, and management of dyspnea.

Parshall MB, Schwartzstein RM, Adams L, Banzett RB, Manning HL, Bourbeau J, Calverley PM, Gift AG, Harver A, Lareau SC, Mahler DA, Meek PM, O'Donnell DE; American Thoracic Society Committee on Dyspnea.

Am J Respir Crit Care Med. 2012 Feb 15;185(4):435-52. doi: 10.1164/rccm.201111-2042ST.

39.

Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD.

Gifford AH, Mahler DA, Waterman LA, Ward J, Kraemer WJ, Kupchak BR, Baird JC.

COPD. 2011 Jun;8(3):160-6. doi: 10.3109/15412555.2011.560132. Epub 2011 Apr 22.

PMID:
21513438
40.

Understanding mechanisms and documenting plausibility of palliative interventions for dyspnea.

Mahler DA.

Curr Opin Support Palliat Care. 2011 Jun;5(2):71-6. doi: 10.1097/SPC.0b013e328345bc84. Review.

PMID:
21430539
41.

Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.

Jones PW, Mahler DA, Gale R, Owen R, Kramer B.

Respir Med. 2011 Jun;105(6):892-9. doi: 10.1016/j.rmed.2011.02.013. Epub 2011 Mar 11.

42.

Mechanism of greater oxygen desaturation during walking compared with cycling in patients with COPD.

Mahler DA, Gifford AH, Waterman LA, Ward J, Machala S, Baird JC.

Chest. 2011 Aug;140(2):351-358. doi: 10.1378/chest.10-2415. Epub 2011 Jan 27.

PMID:
21273296
44.

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.

Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B; INHANCE Study Investigators.

Am J Respir Crit Care Med. 2010 Jul 15;182(2):155-62. doi: 10.1164/rccm.200910-1500OC. Epub 2010 May 12.

PMID:
20463178
45.

American College of Chest Physicians consensus statement on the management of dyspnea in patients with advanced lung or heart disease.

Mahler DA, Selecky PA, Harrod CG, Benditt JO, Carrieri-Kohlman V, Curtis JR, Manning HL, Mularski RA, Varkey B, Campbell M, Carter ER, Chiong JR, Ely EW, Hansen-Flaschen J, O'Donnell DE, Waller A.

Chest. 2010 Mar;137(3):674-91. doi: 10.1378/chest.09-1543. Review.

PMID:
20202949
46.

Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy.

Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA.

Chest. 2010 Jun;137(6):1354-61. doi: 10.1378/chest.09-2470. Epub 2009 Dec 29.

PMID:
20040610
47.

Patient-reported dyspnea in COPD reliability and association with stage of disease.

Mahler DA, Ward J, Waterman LA, McCusker C, ZuWallack R, Baird JC.

Chest. 2009 Dec;136(6):1473-1479. doi: 10.1378/chest.09-0934. Epub 2009 Aug 20.

48.

Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD.

Mahler DA, Murray JA, Waterman LA, Ward J, Kraemer WJ, Zhang X, Baird JC.

Eur Respir J. 2009 Apr;33(4):771-7. doi: 10.1183/09031936.00145208. Epub 2009 Feb 12.

49.

Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD.

Tashkin DP, Donohue JF, Mahler DA, Huang H, Goodwin E, Schaefer K, Hanrahan JP, Andrews WT.

Respir Med. 2009 Apr;103(4):516-24. doi: 10.1016/j.rmed.2008.12.014. Epub 2009 Feb 8.

50.

Are you fluent in the language of dyspnea?

Mahler DA, Baird JC.

Chest. 2008 Sep;134(3):476-477. doi: 10.1378/chest.08-1141. No abstract available.

PMID:
18779189

Supplemental Content

Loading ...
Support Center